Animals are good research subjects for a variety of reasons. They are biologically similar to humans and susceptible to many of the same health problems. An animal model is a non-human species used in biomedical research because it can mimic aspects of a biological process or disease found in humans. It's a tool that researchers use to study diseases and test treatments in cases where human experimentation is not possible and/or unethical. Animal models generate hypotheses as to the developmental, molecular, cellular or physiological effects of a gene on human behavior. Mice and rats make up approximately 95% of all laboratory animals, with mice the most commonly used animal in biomedical research.
The global animal model market was valued at US$ 1,577.30 Mn in 2021 and is forecast to reach a value of US$ 2,394.30 Mn by 2028 at a CAGR of 6.0% between 2022 and 2028.
North America held dominant position in the global animal model market in 2022, accounting for 37.8% share in terms of volume, followed by Europe and Asia Pacific, respectively.
Figure 1. Global Animal Model Market Share (%), by Region, 2022
In October 2020, Taconic Biosciences announced the launch of its first hACE2 model. AC70 mouse experiences a lethal response to SARS-CoV-2 (COVID-19). The new AC22 mouse is lethality-resistant, enabling therapeutic, vaccine, and post-infection symptom research.
In March 2020, Crown Bioscience launched two new liver fibrosis rodent models, allowing more rapid and cost- effective evaluation of the preclinical effects of NASH and anti-fibrotic treatments on acute liver injury, advanced fibrosis, and/or fibrosis reversal.
Animal Model Market Report Coverage
||Market Size in 2021:
||US$ 1,577.30 Mn
|Historical Data for:
||2017 to 2020
||2022 to 2028
|Forecast Period 2022 to 2028 CAGR:
||2028 Value Projection:
||US$ 2,394.30 Mn
- North America: U.S. and Canada
- Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
- Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
- Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
- Middle East: GCC Countries, Israel, and Rest of Middle East
- Africa: South Africa, North Africa, and Central Africa
- By Animal Type: Rat, Mice, Guinea Pigs, Rabbits, and Others
- By Application: Drug Discovery & Development, Basic Research, and Others
- By End User: Pharma & Biotech Companies, Academic Research Institutes, and Others
- By Region: North America, Europe, Asia-Pacific, and LAMEA
Charles River Laboratories International, Inc., The Jackson Laboratory, Taconic Biosciences, JSR Corporation (Crown Bioscience Inc.), Genoway S.A, Eurofins Scientific SE, Envigo, Perkinelmer, Inc. (Horizon Discovery Group), Ozgene Pty Ltd., and Hera Biolabs (Transposagen Biopharmaceuticals), among others.
- Rise in usage of animal models in clinical trials
- The outbreak of COVID-19
|Restraints & Challenges:
- Strict regulations and guidelines
- Growing opposition on animal testing by several organizations
- Rise in usage of animal models in pre-clinical development by several research laboratories and biopharmaceutical industries is expected to augment the growth of the global animal model market during the forecast period. For example, in December 2021, World Health Organization (WHO) launched the SARS-CoV-2 Omicron variant assays and animal models study tracker, even as the highly mutant variant is spreading fast across the globe. WHO is already conducting research studies on variants of the SARS-CoV2 virus.
- Increasing implications of mouse clinical trials for more predictive outcomes is expected to boost the growth of the global animal model market during the forecast period. For example, in January 2020, Taconic Biosciences (Taconic Farms, Inc.), a global leader in providing drug discovery animal model solutions, expanded its premier immuno-oncology portfolio with the launch of the new B2m-NOG mouse model. Immuno-oncology leverages the body’s immune system to fight cancer, increasing the ability to target the disease.
Figure 2. Global Animal Model Market Share (%), by Animal Type, 2022
- Strict regulations and guidelines is expected to hamper growth of the global animal model market. For example, implementation of laws and regulations for animal protection and welfare has led to restrictive practices and restrictions on the use of animals for various purposes. Many countries worldwide have banned the usage of animal models.
- Growing opposition on animal testing by several organizations is expected to hinder growth of the global animal model market. There are many organizations worldwide that are against animal testing. Moreover, a Pew Research Center poll found that around 52% of U.S. adults oppose the use of animal models in scientific research.
- The outbreak of COVID-19 is expected to offer significant growth opportunities for players in the global animal model market. For instance, in April 2021, Taconic Biosciences announced the launch of a new COVID-19 mouse model. This human ACE2 (hACE2) transgenic mouse expands Taconic’s COVID-19 research toolkit. hACE2 AC22 mouse provides a longer study window to assess drug efficacy compared to lethal infection models.
- Increasing number of research and development activities are expected to provide lucrative growth opportunities for players in the global animal model market. For instance, according to the WHO, between 1999 and 2021, the U.S. had the highest total number of trials (157,618), followed by China (80,333) and Japan (57,754). Moreover, in 2021, the U.S. and Germany led R&D (research and development) funding followed by a high-income country for COVID-19 vaccine related research activities.
Market Trends/Key Takeaways:
- Large number of applications in healthcare domain and physiological similarities between human and animal is expected to accelerate growth of the global animal model market during the forecast period. For example, in September 2020, Charles River's Research Models and Services division launched digital animal model ordering platform for North America. It is a giant step to reduce the risk of human error, improve operational communication, and give us better insight into how we can better serve the research community.
- Growing consumption of personalized medicine is expected to propel growth of the global animal model market over the forecast period. For example, the National Precision Medicine program and the Three Beyonds program were launched in Singapore for promoting the uptake of new technologies and digital infrastructure for supporting personalized healthcare.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
- EUROFINS SCIENTIFIC SE
- GENOWAY S.A.
- HERA BIOLABS (TRANSPOSAGEN BIOPHARMACEUTICALS)
- JSR CORPORATION (CROWN BIOSCIENCE INC.)
- OZGENE PTY LTD.
- PERKINELMER, INC. (HORIZON DISCOVERY GROUP PLC.)
- TACONIC BIOSCIENCES
- THE JACKSON LABORATORY
An animal model is a non-human species used in biomedical research because it can mimic aspects of a biological process or disease found in humans. Animals are essential for research that seeks to understand disease progression and treatments. These models are being used in biomedical research to develop novel treatment methods for various chronic diseases. It's a tool that researchers use to study diseases and test treatments in cases where human experimentation is not possible and/or unethical. There are different types of animals used in animal models, such as rat, mice, guinea pigs, rabbits, and others.
Increasing use of animal models due to the increasing number of clinical trials and increase in research and development activities is expected to propel growth of the global animal model market during the forecast period. For instance, in in September 2020, Charles River's Research Models and Services division announced the launch of digital animal model ordering platform for North America to offer an effortless experience to the clients. Moreover, according the U.S. Congressional Budget Office, in 2019, the pharmaceutical industry spent around US$ 83 billion on research and development activities in the United States.
Key features of the study:
- This report provides in-depth analysis of the global animal model market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year.
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global animal model market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include Charles River Laboratories International, Inc., The Jackson Laboratory, Taconic Biosciences, JSR Corporation (Crown Bioscience Inc.), Genoway S.A, Eurofins Scientific SE, Envigo, Perkinelmer, Inc. (Horizon Discovery Group), Ozgene Pty Ltd., and Hera Biolabs (Transposagen Biopharmaceuticals), among others.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global animal model market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global animal model market.
- Global Animal Model Market, By Animal Type:
- Guinea Pigs
- Global Animal Model Market, By Application:
- Drug Discovery & Development
- Basic Research and Others
- Global Animal Model Market, By End User:
- Pharma & Biotech Companies
- Academic Research Institutes
- Global Animal Model Market, By Region:
- North America